These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 29304529)

  • 1. Passivating Injured Endothelium with Kinexins in Thrombolytic Therapy.
    Ma YH; Huang CW; Wen CJ; Lu YC; Wey SP; Wun TC
    Thromb Haemost; 2018 Jan; 118(1):90-102. PubMed ID: 29304529
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fusion proteins comprising annexin V and Kunitz protease inhibitors are highly potent thrombogenic site-directed anticoagulants.
    Chen HH; Vicente CP; He L; Tollefsen DM; Wun TC
    Blood; 2005 May; 105(10):3902-9. PubMed ID: 15677561
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bolus injections of novel thrombogenic site-targeted fusion proteins comprising annexin-V and Kunitz protease inhibitors attenuate intimal hyperplasia after balloon angioplasty.
    Yeh YH; Chang SH; Chen SY; Wen CJ; Wei FC; Tang R; Achilefu S; Wun TC; Chen WJ
    Int J Cardiol; 2017 Aug; 240():339-346. PubMed ID: 28433556
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Novel Injury Site Targeted Fusion Protein Comprising Annexin V and Kunitz Inhibitor Domains Ameliorates Ischemia-Reperfusion Injury and Promotes Survival of Ischemic Rat Abdominal Skin Flaps.
    Shyu VB; Hsu CE; Wen CJ; Wun TC; Tang R; Achilefu S; Wei FC; Cheng HY
    Ann Plast Surg; 2017 Mar; 78(3 Suppl 2):S129-S134. PubMed ID: 28166139
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Potent cardioprotection from ischemia-reperfusion injury by a two-domain fusion protein comprising annexin V and Kunitz protease inhibitor.
    Yeh CH; Chen TP; Wang YC; Fang SW; Wun TC
    J Thromb Haemost; 2013 Aug; 11(8):1454-63. PubMed ID: 23746209
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Thrombolysis by chemically modified coagulation factor Xa.
    Pryzdial EL; Meixner SC; Talbot K; Eltringham-Smith LJ; Baylis JR; Lee FM; Kastrup CJ; Sheffield WP
    J Thromb Haemost; 2016 Sep; 14(9):1844-54. PubMed ID: 27359348
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Investigation of a potential scintigraphic tracer for imaging apoptosis: radioiodinated annexin V-Kunitz protease inhibitor fusion protein.
    Liao MH; Jan TR; Chiang CC; Yen KC; Liao TZ; Chen MW; Chi CW; Wun TC; Yen TC; Wey SP
    J Biomed Biotechnol; 2011; 2011():675701. PubMed ID: 21584284
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Selective inhibition of factor Xa is more efficient than factor VIIa-tissue factor complex blockade at facilitating coronary thrombolysis in the canine model.
    Lefkovits J; Malycky JL; Rao JS; Hart CE; Plow EF; Topol EJ; Nicolini FA
    J Am Coll Cardiol; 1996 Dec; 28(7):1858-65. PubMed ID: 8962577
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Preparation of Peptide and Recombinant Tissue Plasminogen Activator Conjugated Poly(Lactic-Co-Glycolic Acid) (PLGA) Magnetic Nanoparticles for Dual Targeted Thrombolytic Therapy.
    Chen HA; Ma YH; Hsu TY; Chen JP
    Int J Mol Sci; 2020 Apr; 21(8):. PubMed ID: 32294917
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Thrombolysis induced by intravenous administration of plasminogen activator in magnetoliposomes: dual targeting by magnetic and thermal manipulation.
    Liu CH; Hsu HL; Chen JP; Wu T; Ma YH
    Nanomedicine; 2019 Aug; 20():101992. PubMed ID: 30981818
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fibrin-targeted direct factor Xa inhibition: construction and characterization of a recombinant factor Xa inhibitor composed of an anti-fibrin single-chain antibody and tick anticoagulant peptide.
    Hagemeyer CE; Tomic I; Jaminet P; Weirich U; Bassler N; Schwarz M; Runge MS; Bode C; Peter K
    Thromb Haemost; 2004 Jul; 92(1):47-53. PubMed ID: 15213844
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of enoxaparin, hirulog, and heparin as adjunctive antithrombotic therapy during thrombolysis with rtPA in the stenosed canine coronary artery.
    Leadley RJ; Kasiewski CJ; Bostwick JS; Bentley R; McVey MJ; White FJ; Perrone MH; Dunwiddie CT
    Thromb Haemost; 1997 Oct; 78(4):1278-85. PubMed ID: 9364998
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Conjunctive enhancement of enzymatic thrombolysis and prevention of thrombotic reocclusion with the selective factor Xa inhibitor, tick anticoagulant peptide. Comparison to hirudin and heparin in a canine model of acute coronary artery thrombosis.
    Sitko GR; Ramjit DR; Stabilito II; Lehman D; Lynch JJ; Vlasuk GP
    Circulation; 1992 Feb; 85(2):805-15. PubMed ID: 1735171
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Characterisation of a novel series of aprotinin-derived anticoagulants. I. In vitro and pharmacological properties.
    Stassen JM; Lambeir AM; Matthyssens G; Ripka WC; Nyström A; Sixma JJ; Vermylen J
    Thromb Haemost; 1995 Aug; 74(2):646-54. PubMed ID: 8585001
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combination of platelet fibrinogen receptor antagonist and direct thrombin inhibitor at low doses markedly improves thrombolysis.
    Nicolini FA; Lee P; Rios G; Kottke-Marchant K; Topol EJ
    Circulation; 1994 Apr; 89(4):1802-9. PubMed ID: 8149546
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Potent bifunctional anticoagulants: Kunitz domain-tissue factor fusion proteins.
    Lee GF; Lazarus RA; Kelley RF
    Biochemistry; 1997 May; 36(19):5607-11. PubMed ID: 9153400
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Thrombolysis and reocclusion in experimental jugular vein and coronary artery thrombosis. Effects of a plasminogen activator inhibitor type 1-neutralizing monoclonal antibody.
    Biemond BJ; Levi M; Coronel R; Janse MJ; ten Cate JW; Pannekoek H
    Circulation; 1995 Feb; 91(4):1175-81. PubMed ID: 7850956
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Procoagulant activity on injured arteries and associated thrombi is mediated primarily by the complex of tissue factor and factor VIIa.
    Speidel CM; Thornton JD; Meng YY; Eisenberg PR; Edgington TS; Abendschein DR
    Coron Artery Dis; 1996 Jan; 7(1):57-62. PubMed ID: 8773434
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bioconjugation of recombinant tissue plasminogen activator to magnetic nanocarriers for targeted thrombolysis.
    Yang HW; Hua MY; Lin KJ; Wey SP; Tsai RY; Wu SY; Lu YC; Liu HL; Wu T; Ma YH
    Int J Nanomedicine; 2012; 7():5159-73. PubMed ID: 23055728
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Recombinant Tissue Plasminogen Activator-conjugated Nanoparticles Effectively Targets Thrombolysis in a Rat Model of Middle Cerebral Artery Occlusion.
    Deng J; Mei H; Shi W; Pang ZQ; Zhang B; Guo T; Wang HF; Jiang XG; Hu Y
    Curr Med Sci; 2018 Jun; 38(3):427-435. PubMed ID: 30074208
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.